Progenra
Biotechnology, 271 a Great Valley Parkway, Malvern, Pennsylvania, 19355, United States, 11-50 Employees
Phone Number: 61********
Who is PROGENRA
Ubiquitin-based drug discovery, such as Protein Targeting Chimeras (PROTAC) is at the exciting initial stages. PROTAC drugs are, hetero-bifunctional small molecules that bind at one end t...
Read More
-
Headquarters: 271 a Great Valley Parkway, Malvern, Pennsylvania, 19355, United States
-
Date Founded: 2005
-
Employees: 11-50
-
Revenue: $5 Million to $10 Million
-
Active Tech Stack: See technologies
-
CEO:
Tauseef Butt
Email
Phone
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 541714 |
Show More
Progenra Org Chart and Mapping
Similar Companies to Progenra
Arbutus Biopharma Corporation
-
51-200
-
$ 50 Million to 100 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Progenra
Answer: Progenra's headquarters are located at 271 a Great Valley Parkway, Malvern, Pennsylvania, 19355, United States
Answer: Progenra's phone number is 61********
Answer: Progenra's official website is https://progenra.com
Answer: Progenra's revenue is $5 Million to $10 Million
Answer: Progenra's SIC: 2836
Answer: Progenra's NAICS: 541714
Answer: Progenra has 11-50 employees
Answer: Progenra is in Biotechnology
Answer: Progenra top competitors include: Arbutus Biopharma Corporation
Answer: Progenra contact info: Phone number: 61******** Website: https://progenra.com
Answer: Ubiquitin-based drug discovery, such as Protein Targeting Chimeras (PROTAC) is at the exciting initial stages. PROTAC drugs are, hetero-bifunctional small molecules that bind at one end to an E3 ligase and at the other end to a protein meant to be degraded for therapeutic effect, has added a new dimension to proteostasis-based therapy. PROTACs have several advantages over simple DUB or E3 inhibitors or activators, including catalytic mechanism of action, reduced susceptibility to resistance owing to target mutation, and pharmacologic activity at concentrations lower than those usually needed for simple enzyme effectors. Progenra is developing a new class of PROTAC molecules that have demonstrated cell proof of concept and are now in the preclinical development stage. The drug discovery platform is complemented by internal biochemical, biological target validation programs and medicinal chemistry/lead optimization.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month